AstraZeneca's Lynparza Response Rate Beats Chemotherapy In Trial
LONDON (Alliance News) - AstraZeneca PLC on Tuesday said its Lynparza drug produced a higher objective response rate than chemotherapy in advanced ovarian cancer and improved progression-free a of Read More